The key molecular events required for the formation of ductal carcinoma in situ (DCIS) and its progression to invasive breast carcinoma have not been defined. Here, we show that the nuclear receptor coactivator amplified in breast cancer 1 (AIB1) is expressed at low levels in normal breast but is highly expressed in DCIS lesions. This is of significance since reduction of AIB1 in human MCFDCIS cells restored a more normal three-dimensional mammary acinar structure. Reduction of AIB1 in MCFDCIS cells, both before DCIS development or in existing MCFDCIS lesions in vivo, inhibited tumor growth and led to smaller, necrotic lesions. AIB1 reduction in MCFDCIS cells was correlated with significant reduction in the CD24 À /CD44 þ breast cancer-initiating cell (BCIC) population, and a decrease in myoepithelial progenitor cells in the DCIS lesions in vitro and in vivo. The loss of AIB1 in MCFDCIS cells was also accompanied by a loss of expression of NOTCH 2, 3 and 4, JAG2, HES1, GATA3, human epidermal growth factor receptor 2 (HER2) and HER3 in vivo. These signaling molecules have been associated with differentiation of breast epithelial progenitor cells. These data indicate that AIB1 has a central role in the initiation and maintenance of DCIS and that reduction of AIB1 causes loss of BCIC, loss of components of the NOTCH, HER2 and HER3 signaling pathways and fewer DCIS myoepithelial progenitor cells in vivo. We propose that increased expression of AIB1, through the maintenance of BCIC, facilitates formation of DCIS, a necessary step before development of invasive disease.
INTRODUCTION
There are 450 000 new cases of ductal carcinoma in situ (DCIS) diagnosed every year in the United States. In DCIS lesions, the lumen of the mammary ducts is filled with proliferative malignant cells that have not invaded beyond the basement membrane of the duct into the adjacent stroma. Based on the epidemiology, pathology and assessment of shared genetic changes between DCIS and adjacent invasive lesions, DCIS has been identified as the precursor lesion for invasive breast cancer. [1] [2] [3] Extensive comparative gene expression analyses to date have not defined the critical driver pathways that are needed for the development and maintenance of DCIS and its further progression to invasive carcinoma. 4, 5 However, DCIS and invasive disease share a similar gene expression profile, whereas the expression profiles of normal breast and DCIS are significantly different. 6 This suggests that many of the important signaling changes that are required for the development of invasive and even metastatic disease occurred during the formation of DCIS.
AIB1 is the third member of the nuclear coactivator-3 (NCOA-3) and p160 steroid receptor coactivator-3 (SRC-3) family. The AIB1 oncogene is located on chromosome 20q, a region frequently amplified in breast cancer. 7 AIB1 is a transcriptional coactivator that promotes the transcriptional activity of multiple nuclear receptors such as the estrogen receptor (ER) and progesterone receptor (PR), 7 and a number of other transcription factors, including E2F-1, AP-1, NF-kB and STAT6. 8 Multiple studies have shown that the AIB1 gene is amplified and overexpressed in human breast cancer. 9 High levels of AIB1 mRNA or protein predict significantly worse prognosis and overall survival in breast cancer patients. 9 Transgenic mice expressing high levels of the human AIB1 transgene developed mammary hyperplasia and tumors of the mammary gland. 10 Conversely, loss of AIB1 expression in the mammary gland prevents RAS-or human epidermal growth factor receptor 2 (HER2)-induced mammary tumor development. 11, 12 Transgenic mice expressing high level of an AIB1 isoform in the mammary gland resulted in the development of DCIS and fibrosis. 13 In this study, we determined that AIB1 is highly expressed in human DCIS samples. Based on these observations, we hypothesized that AIB1 could be important in the early stages of breast cancer, notably in the development and maintenance of DCIS. We have examined the role of AIB1 in a well-described model of human DCIS, MCFDCIS.com (MCFDCIS) cells, which are a derivative of premalignant MCF-10AT cells, that when implanted in mice produce discrete DCIS lesions that rapidly progress to invasive disease. 14 The gross pathology of the lesions and the gene expression changes observed in the DCIS stage of MCFDCIS after implantation mirror those seen in human DCIS samples. 15 Using this model, we demonstrate that AIB1 is critical for the formation and maintenance of DCIS. AIB1 is required to maintain the breast cancer-initiating cell (BCIC) population and the myoepithelial progenitor cell population in the MCFDCIS cells in vitro and in vivo.
In parallel, AIB1 also maintains levels of NOTCH and HER2/HER3 signaling molecules in the DCIS lesions. These pathways are known to be involved in maintaining BCIC populations. Based on these data, we propose that preventive strategies aimed at reducing AIB1 in the mammary gland could be selective and effective in reducing DCIS incidence and consequently decreasing the overall incidence of invasive breast cancer.
RESULTS

AIB1 expression in human DCIS
To determine the expression levels of AIB1 in human DCIS, we obtained paraffin-embedded sections of DCIS patient samples. We determined that the AIB1 levels in normal breast ducts, detected by immunohistochemistry (IHC), were very low ( Figure 1Aa ). In contrast, strong AIB1 expression was observed in the luminal cells of DCIS lesions from patients with invasive breast cancer (Figure 1Ab -f). ER þ , HER2-positive (HER2 þ ) and ER À , HER2 À and PR À 'triplenegative' invasive breast cancer samples all showed strong AIB1 staining (Figure 1Ab -f). Strong AIB1 staining was also observed in breast tissue samples from DCIS patients who had no evidence of invasive disease (Supplementary Figure S1Aa-d ). The staining for AIB1 in the DCIS samples was high in the nuclear or cytoplasmic compartments, but patterns of AIB1 subcellular distribution did not appear to be associated with a particular breast cancer subtype. Previous reports have shown that AIB1 and its isoform can traverse between different cellular compartments, depending on stage of cell cycle and cellular expression of other coregulators. [16] [17] [18] Overall, our IHC results indicate that AIB1 protein is highly expressed at very early stages of human breast cancer progression before development of stage 1 invasive disease, and this suggests that AIB1 could function in an early stage of breast cancer formation.
To determine the role of AIB1 in early-stage breast cancer, we utilized the MCFDCIS cell model of breast cancer. 14 When implanted subcutaneously, MCFDCIS cells give well-defined DCIS lesions that progress to invasive disease within 3-5 weeks 19 ( Figure 1B) . The ductal lesions that develop after 3 weeks implantation of MCFDCIS cells resemble high-grade comedo DCIS (Figure 1Ba Figure S1B ). The presence of AIB1 protein was confirmed by western blot analysis of MCFDCIS cells in vitro ( Figure 1D (left)) and in MCFDCIS tumor extracts ( Figure 1D (right)). AIB1 was also detected in the invasive lesions that developed from the MCFDCIS cells in vivo, although the staining was less intense than in the DCIS lesions ( Figure 1C (lower panel)). Fluorescence in situ hybridization (FISH) analysis revealed that the MCFDCIS cells do not have amplified copies of either AIB1 ( Figure 1E ) or HER2 (Supplementary Figure S1C) . The MCFDCIS lesions are PR À (Supplementary Figure S1D) and have low levels of ERa ( Supplementary Figures S2A and B ). MCFDCIS tumor growth is estrogen-independent as it is unaffected by ovariectomy ( Supplementary Figures S2C and D) or by treatment of mice with the estrogen antagonist fulvestrant ( Supplementary Figures S2E-G) . These observations are consistent with a previous classification of the MCFDCIS lesions as a basal form of human DCIS. 15 AIB1 has a role in the maintenance of DCIS multiacinar structures in a 3D matrix We first examined the impact of changing AIB1 levels in mammary acinar three-dimensional (3D) structures. Normal mammary epithelial cells, such as MCF-10A, grown in Matrigel (BD Biosciences, San Jose, CA, USA), recapitulate features of normal breast, including polarized acini, and deposition of basement membrane characterized by laminin V. After a number of days of growth, the acini develop a hollow lumen characteristic of the lumen seen in mammary acini in vivo 20 (Figures 2A (upper panel) and 2Ca and e). The overexpression of oncogenes, such as HER2, disrupts normal mammary acinar structure and instead larger, multiacinar structures are observed, with filled lumen and irregular deposition of basement membrane proteins. 21 The MCFDCIS cells grown in Matrigel showed multiacinar structures, with no lumen development and with deposition of laminin throughout the multiacinar structure (Figures 2A (lower panel) and 2Cb and f). To determine the impact of AIB1 on maintenance of the DCIS phenotype in Matrigel, we infected MCFDCIS cells with a lentiviral vector expressing two distinct AIB1 short hairpin RNAs (shRNAs) (shAIB1-1 and shAIB1-2) that lowered the endogenous AIB1 levels by 40% and 70%, respectively ( Figure 2B ). Reduction in AIB1 levels after shAIB1-1 infection showed some changes in laminin V distribution to the periphery of the acini (Figure 2Cg ), but with the more effective shRNA AIB1-2, a more normal spheroid acinar structure was observed (Figure 2Cd and h). The average spheroid size of MCFDCIS shAIB1-2 spheroids was also significantly smaller than MCFDCIS shCTRL and similar to the average size seen in MCF-10A ( Figure 2D ). Consistent with this, overexpression of AIB1 in MCF-10A ( Figure 2E ) caused loss of polarization and an increase in highly disorganized acini in 3D culture (Figure 2Fb and d). Interestingly, in the MCFDCIS shAIB1 spheroids, we observed caspase 3-positive apoptotic cells, especially in the center of the sphere (Supplementary Figure S3A ) and an increased expression of the apoptotic marker BIM EL and the cell cycle inhibitor p21 (Supplementary Figure S3B) . Changes in expression of these molecules have been associated with resumption of a more normal mammary acinar structure with the hollow lumen being created by increased apoptosis. 20 Overall, the data indicate that high AIB1 levels in the MCFDCIS cells are required to maintain a disorganized multiacinar structure in Matrigel and reduction of AIB1 levels can partially restore normal mammary acinar structure in MCFDCIS cells.
AIB1 is required for the formation of DCIS lesions in vivo
We next determined if the loss of AIB1 in MCFDCIS cells could affect MCFDCIS tumor development in vivo. To examine this, we infected the MCFDCIS cell line with a lentiviral vector ( Figure 3A ). In these pooled selected cells, AIB1 mRNA and protein levels are constitutively depleted ( Supplementary Figures S4A and B ). Cells were injected subcutaneously into nude mice and the tumors monitored for up to 24 weeks or to the time that they exceeded the size of 500 mm 3 ( Figure 3B ). The control-infected cells grew rapidly and all of the tumors had reached 500 mm 3 volume by 7 weeks after implantation ( Figure 3C ). In contrast, the AIB1 shRNA-infected cells grew slowly and 20% of the tumor injection sites had not developed lesions 4500 mm 3 by 24 weeks ( Figure 3C ). Tumors from the control animals had the characteristic comedo DCIS lesions ( Figure 3D (upper panel)). DCIS lesions were also observed in the shAIB1 cells, but they were of a significantly smaller area (Figures 3D (lower panel) and E), with less overall prevalence (Supplementary Figure S4C ), and more necrosis than the control ( Figure 3F ). We also observed a decrease in the number of proliferative cells in the MCFDCIS AIB1 shRNA lesions as determined by the quantitation of overall proliferating cell nuclear antigen staining ( Figure 3G ) and the percentage of p21-positive cells (Supplementary Figure S4D) . These data indicate that MCFDCIS cells with low AIB1 levels will not progress to invasive tumors as rapidly as the control cells. Furthermore, the DCIS lesions that develop in the presence of lower levels of AIB1 will be smaller and more necrotic.
AIB1 is required for the maintenance of DCIS lesions in vivo
We next asked whether reduction of AIB1 in MCFDCIS cells would impact on the maintenance of DCIS lesions once they have 
Loss of AIB1 causes reduction in the BCIC population of MCFDCIS and affects MCFDCIS cell differentiation
To investigate how AIB1 affects initiation and progression of DCIS, we compared global gene expression changes in MCFDCIS cells ± AIB1 shRNA in vitro using cDNA array analysis. Notable among the most significant expression changes between the two groups were genes that are differentially expressed in BCIC such as CD24 22 and members of the NOTCH signaling pathway (DLL1 and DLL3) 23 ( Supplementary Table S1 ). Luminal progenitor marker expression, such as mucin 1, 24 was also increased ( Supplementary  Table S1 ). To determine if these expression changes impacted the population of BCIC, we fluorescence-activated cell-sorted MCFDCI-S ± AIB1 shRNA cells for CD24 À /CD44 þ ( Figure 5A ). Reduction of AIB1 levels caused the percentage of CD24 À /CD44 þ cells in the MCFDCIS population to drop substantially from 18% to o3% ( Figure 5A ). Consistent with a loss of BCIC, the CD44 and CD49f levels were also significantly reduced in MCFDCIS AIB1shRNA cells ( Figure 5B (upper panel) ). In contrast, the level of expression of CD24 and ESA on their cell surface was increased ( Figure 5B (lower panel) ).
There was also an increase in overall expression of mucin 1 mRNA in Figure 5C (left panel) ). CD24 and ESA, like mucin 1, are considered luminal cell markers and the gain in their expression after AIB1 reduction suggested that there were changes in relative levels of progenitor luminal vs progenitor myoepithelial cells in MCFDCIS population. Consistent with a role for AIB1 in BCIC maintenance, overexpression of AIB1 in MCF-10A cells led to increased sphere formation and increased expression of CD44 and CD49f ( Supplementary Figures S6A and B) .
To determine if the changes in BCIC cell populations were observed after AIB1 reduction in vivo, we stained MCFDCIS tumors obtained from the constitutive and conditional mouse models for CD44, CK18 and p63 expression ( Figure 5D and Supplementary Figure S6C ). A significant reduction in overall CD44 staining in the smaller lesions that developed in MCFDCIS AIB1 shRNA cells implanted in vivo is also consistent with BCIC loss (Figure 5Db and Supplementary Figure S6Cb ). Interestingly, in the MCFDCIS AIB1 shRNA lesions, there was a gain in vivo in the CK18 staining, a marker of differentiated luminal epithelium (Figure 5Dd , Supplementary Figures S6Cd and D) . In contrast, myoepithelial progenitor cells were significantly reduced in AIB1 shRNA cells, indicated by the loss of overall expression of a-smooth muscle actin mRNA in vitro ( Figure 5C (right panel) ) and the loss of p63-positive cells in vivo (Figure 5Df and Supplementary Figures  S6E and F) .
In summary, the loss of AIB1 in MCFDCIS cells in vitro and in vivo reduces the BCIC and myoepithelial progenitor populations and also prevents the progression of the remaining luminal cells to invasive cancer. Table S1 ). This was of interest since the NOTCH signaling pathway has been shown to be involved in BCIC cell maintenance and differentiation. 23 We therefore examined the impact of reduction in AIB1 expression in MCFDCIS cells in vitro and in vivo on the gene expression pattern of a panel of NOTCH signaling molecules. Downregulation of DLL1, DLL3, JAG1 and JAG2 mRNA levels was confirmed by real-time PCR in MCFDCIS cells upon shRNA AIB1 expression ( Figure 6A ). Consistent with this, overexpression of AIB1 in MCF-10A results in an increase in DLL1, DLL3, NOTCH 2, JAG1 and JAG2 mRNA levels ( Figure 6B ). In the MCFDCIS tumors, we also observed JAG2, NOTCH 2, 3 and 4 mRNA levels downregulated ( Figure 6C ) as well as the NOTCH target genes HES1 and GATA3 ( Figure 6C ). Previous reports have indicated that HER2 and HER3 control the level of NOTCH signaling in BCIC. 23 Thus, it was possible that changes in AIB1 levels were affecting HER2 and HER3 signaling, and this in turn was altering the expression of members of the NOTCH pathway. We determined that HER2 and HER3 mRNA and protein were detectable by PCR and western blot analysis in MCFDCIS cells and tumors ( Supplementary Figure S7A and Figures 6D and E) . A significant reduction in HER2 and HER3 mRNA and protein levels are observed in the MCFDCIS tumors after reduction in AIB1 levels ( Figures 6D and E and Supplementary Figures S7C-F) , whereas EGFR Figure S7G ). Furthermore, a clear positive correlation between AIB1 mRNA and HER2 and HER3 mRNA levels was found in the tumors (Figures 6D and E) . Consistent with this, we demonstrated that HER2 mRNA and protein are upregulated in MCF-10A cells infected with lentivirus-expressing AIB1 (Supplementary Figure S7H) . In summary, reduction in AIB1 levels in MCFDCIS tumors in vivo leads to the loss of HER2, HER3 as well as the loss of NOTCH signaling pathway members. These changes in gene expression are paralleled by a significant loss in BCIC population and myoepithelial progenitor cells.
Disruptions in NOTCH and HER signalings are observed in MCFDCIS AIB1 shRNA cells and tumors cDNA array analysis of gene expression changes induced by the loss of AIB1 in MCFDCIS cells indicated that NOTCH ligands (DLL1 and DLL3) were significantly downregulated (Supplementary
DISCUSSION
This is the first report that defines a role for AIB1 in the development and maintenance of human DCIS. Although AIB1 is known to be involved in the proliferation of a number of different epithelial tumors, 25 the role of AIB1 in the maintenance of BCIC has not been reported previously. The loss of the BCIC population in MCFDCIS tumors with reduced levels of AIB1 most likely leads to the reduced size of DCIS lesions and the loss of overall MCFDCIS tumor burden because of increased necrosis. While increased necrosis is often seen in the lumen of DCIS lesions in vivo, the necrosis we observed was more associated with the inability to sustain the DCIS cells, thus inhibiting their progression to invasive lesions. Interestingly, reduction of AIB1 after formation of DCIS lesions also causes formation of smaller lesions, reduced tumor burden and increased necrosis. This suggests that sustaining the BCIC population is required throughout DCIS development, not just after initial implantation of the cells in vivo. This has important therapeutic implications as it suggests that a reduction of AIB1 or inhibition of AIB1 signaling pathways involved in the maintenance of BCIC would hamper development of DCIS. It should be noted The nuclear coactivator amplified in breast cancer 1 V Ory et al that only 20-30% of human DCIS is thought to progress to invasive disease 26 and this raised the question of the role of AIB1 in the progression of DCIS to invasive disease. Although MCFDCIS cells can give rise to invasive lesions in vivo, they have low motility in a Boyden chamber invasion assay (Supplementary Figure S8A ) and low invasion potential in an endothelial layer in an electric cell-substrate impedance sensing assay compared with invasive MDA-MB-231 cells (Supplementary Figure S8B) . It is also known that MCFDCIS cells have low cell velocity in the wound healing assay. 27 Consistent with this low motile potential of MCFDCIS, no micrometastases were observed after tumor formation in vivo (Supplementary Figure S8C ). We found that reduction in AIB1 did not affect these minimal phenotypes of MCFDCIS cells in either the in vitro invasion or motility assays ( Supplementary  Figures S8A and B ). However, AIB1 may have an additional role in epithelial cell invasion in the context of stroma that is not apparent in these assays. As AIB1 is highly expressed in the patient DCIS samples that we have examined to date, and its loss prevents MCFDCIS invasive tumor development, we can conclude that AIB1 overexpression is necessary primarily for the development and maintenance of DCIS through preserving the BCIC population, but further genetic changes are most likely necessary for the development of the invasive phenotype in a subset of DCIS. Our analysis of gene expression controlled by changes in AIB1 levels in MCFDCIS cells revealed that members of the NOTCH pathways are regulated by AIB1. This was confirmed by analysis of the in vivo samples, although interestingly the patterns of changes in NOTCH signaling molecules in vivo did not parallel the changes seen in vitro. Although NOTCH 1 was not regulated by AIB1 in vitro or in vivo, notably NOTCH 2, 3 and 4, and JAG2 were significantly downregulated in vivo. We conjecture that the regulation of NOTCH by AIB1 in vivo requires crosstalk with stromal components The nuclear coactivator amplified in breast cancer 1 V Ory et al that are vital to the maintenance of DCIS in vivo. NOTCH signaling has been implicated in both restricting mammary stem cell expansion and has been associated with commitment of mammary stem cells to the luminal lineage, leading to hyperplasia and tumor formation. 28 In implanted MCFDCIS in which AIB1 was lowered, we did observe a decrease in hyperplasia and a decrease in the number of tumors, although we did not see eradication of luminal cells, which might be expected with a significant reduction in NOTCH signaling. Interestingly, recent reports have demonstrated that the NOTCH pathway can be controlled by HER family signaling in breast cancer stem cells 29 and in DCIS. 30 AIB1 is required for HER2-mediated mammary tumor formation in vivo 11, 12 and high levels of AIB1 and HER2 have been associated with worse prognosis and tamoxifen resistance in human breast cancer. 9 Overexpression of HER2 is seen in significant portion of DCIS cases estimated at 50-80%. 31 However, an association between AIB1 and HER2 in the development of DCIS and its progression to invasion has not been established. In our gene expression analysis of ±AIB1 in MCFDCIS cells in vitro, major changes in the expression of HER family members HER1, 2 and 3 were not observed. However, a reduction in vivo in AIB1 led to loss in HER2 and HER3 expression, again suggesting the importance of stromal crosstalk in determining levels of gene expression in DCIS. HER2 signaling can regulate mammary stem cell renewal 32 and loss of HER2 signaling controlled by the loss of AIB1 could explain the significant loss of BCIC in vivo. Interestingly, HER3 has recently been shown to have a role in maintaining luminal epithelium cells, and loss of HER3 signaling causes a switch to mammary basal epithelium gene expression patterns. 33 Thus, the loss of HER3 signaling in vivo may also have a role in overall loss of luminal cells, although it would not explain the decrease in the myoepithelial progenitor layers in the AIB1-depleted lesions. We tried to rescue BCIC loss caused by reduced AIB1 with overexpressed HER2 but were unable to increase HER2 expression in the shAIB1 cells (Supplementary Figure S7I) , presumably because the CMV promoter-regulating HER2 expression in the lentiviral vector is also dependent on AIB1. Nevertheless, the data in Figure 6 and Supplementary Figure S7 strongly implicate a connection between AIB1, HER2/3 and NOTCH in the development and maintenance of DCIS. Previous studies in transgenic mice indicated that overexpression of AIB1 can lead to DCIS 13 and we now show that human DCIS has high expression of AIB1 at the protein level. Five to ten percent of breast cancers harbor an AIB1 amplicon, 7 although high AIB1 levels can be observed in the absence of gene amplification in up to 60% of breast cancer. AIB1 protein levels are regulated by multiple post-transcriptional mechanisms that control steady-state levels of AIB1 during the transformation process. 8 AIB1 levels in cells can be downregulated by estrogen. 34 However, loss of estrogen regulation does not seem to be the explanation of high AIB1 in DCIS, as we observed high AIB1 levels in ER þ and ER À DCIS as well as HER2 þ and HER2 À DCIS. A previous study examining ERa knockout mice demonstrated that ER signaling was necessary for the formation of DCIS. 35 Our group also published a study in which development of DCIS and invasive mammary cancer was correlated with overexpression of AIB1 with ERa in transgenic mice. 13 This study extends these observations demonstrating that AIB1 overexpression can also contribute to the development of the basal form of DCIS. Thus, the contribution of AIB1 overexpression to DCIS development and maintenance is not breast cancer subtype-specific. In conclusion, regardless of the mechanism of upregulation of AIB1 in human breast epithelium, our data indicate a critical role for this event in the development and maintenance of DCIS lesions in vivo through preservation of BCIC in part through NOTCH, HER2 and HER3 signaling. Our data suggest that selective degradation of AIB1 in early breast cancer lesions could be a useful therapeutic approach to prevent the development and maintenance of DCIS, thus reducing the overall incidence of invasive breast cancer.
MATERIALS AND METHODS
Human tissue samples and mice
De-identified formalin-fixed, paraffin-embedded tissues from normal breast reduction mammoplasty and DCIS were obtained from Georgetown University tissue bank-shared resource. Athymic nude mice were obtained from Harlan Laboratories (Frederick, MD, USA) were maintained in the Georgetown University's animal facility and animal experiments were conducted in accordance with procedures approved by the Institutional Animal Care and Use Committee.
Cell lines
We thank Dr Fred R Miller of the Karmanos Cancer Institute for the gift of the MCFDCIS and MCF-10A cell lines. These cells were maintained as described previously. 36, 37 Histology analysis Hematoxylin and eosin, IHC and immunofluorescence analyses were performed on paraffin-embedded 5-mm sections using standard protocols described elsewhere. 12 
Western blot
Whole-cell extracts were isolated from cultured MCFDCIS, MCF-7 and MCF-10A cells or DCIS tumor samples, and immunoblot assays were performed as described previously. 38 
FISH analysis
FISH hybridization and analysis were performed in the MCFDCIS cells using a standard protocol described previously. 39, 40 shRNA constructs and lentivirus infection For gene downregulation studies, shRNAs against AIB1 gene (shRNA no. 1 5 0 -GCAGTCTATTCGTCCTCCATA-3 0 ; shRNA no. 2: 5 0 -TGGTGAATCGAGACG GAAACA-3 0 ) were cloned into PLKO.1 lentiviral vector (Addgene, Cambridge, MA, USA) as described in Al-Otaiby et al. 41 or into XhoI and EcoRI restriction sites in Dox-inducible lentiviral expression vector pTRIPZ (Open Biosystems, Thermo Fisher Scientific Inc.,). A scrambled shRNA was used as a control (Addgene). For gene overexpression, the coding sequence of human AIB1 was cloned into AscI and PacI restriction sites in the lentiviral expression vector pCDF1-MSC2-EF1-Puro (System Biosciences, Mountain View, CA, USA). Lentivirus production and infection were performed as described elsewhere. 36, 42 Xenografts MCFDCIS xenograft models were generated as detailed in Figures 3B and 4B following the protocol described presviously. 15 Analysis of 3D Matrigel cultures by bright-field and confocal microscopy 3D culture assays were performed as described previously. 36, 37 For confocal microscopy, immunostaining of the acinar structures was carried out as described elsewhere. 43 Quantitative RT-PCR Real-time quantitative RT-PCR analyses of total cellular RNA from MCFDCIS cells, MCF-10A cells and DCIS xenografted tissues was carried out as described previously. 41 All of the primers used for quantitative RT-PCR are given in Supplementary Table S2 . The results were calculated by the comparative CT method, with relative transcript levels determined as 2 À DDCT and were normalized using actin gene. 44 Flow cytometry analysis MCFDCIS cells were stained with the following antibodies: anti-CD24-488, anti-CD44-PE, anti-CD49f-APC, anti-ESA-488 and anti-CD10-PE (BioLegend, San Diego, CA, USA). Fluorescence-activated cell sorter analysis was
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